Abstract:Tingyu Cao, 1 Zengguang Wang, 2 Xiaodong Zhu 1 1 Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China; 2 Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China Correspondence: Xiaodong Zhu, Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China, Tel +86 13312142939, Email Zengguang Wang, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China, Email Bruton's tyrosine kinase (BTK) is a central signaling node in B cells. BTK inhibition has witnessed great success in the treatment of B-cell malignancies. Additionally, in the immune system, BTK is also a prominent component linking a wide variety of immune-related pathways. Therefore, more and more studies attempting to dissect the role of BTK in autoimmune and inflammation progression have emerged in recent years. In particular, BTK expression was also found to be elevated within the central nervous system (CNS) during neuroinflammation. BTK inhibitors are capable of crossing the blood–brain barrier rapidly to modulate B cell functions, attenuate microglial activities and affect NLRP3 inflammasome pathways within the CNS to improve the outcome of diseases. Thus, BTK inhibition appears to be a promising approach to modulate dysregulated inflammation in the CNS and alleviate destruction caused by excessive inflammatory responses. This review will summarize the immunomodulatory mechanisms in which BTK is involved in the development of neurological diseases and discuss the therapeutic potential of BTK inhibition for the treatment of neuroinflammatory pathology. Keywords: BTK, BTK inhibition, BTK inhibitors, neuroinflammation Bruton's tyrosine kinase (BTK), encoded by the BTK gene, is a cytoplasmic non-receptor tyrosine kinase of the Tec kinase family. As an integral part of BCR signaling, BTK plays vital roles in governing B cell development, proliferation and function. Its name originates from Ogden Bruton, who first described the disease X-linked agammaglobulinemia (XLA) in 1952 1 . This condition was characterized by recurrent bacterial infection because of the absence of antibodies in the serum. Further studies revealed an arrest of B cell development and differentiation in XLA patients and X-linked immunodeficiency (xid) mice. 2,3 Later, the mutation of BTK was identified as the culprit causing this humoral immunity deficiency in xid mice and XLA patients. 2,4 Due to the central role of BTK in B-cell maturation and function, various types of BTK inhibitors have been discovered and finally approved for the therapeutics of hematogenic malignancies, especially those related to B cells, such as chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM) and mantle cell lymphoma, etc. 5 BTK-related signaling also participates in the cascade of autoimmunity and inflammation. In addition to B cells. BTK is also expressed in other immune cells including neutrophils, macrophages, mast cells and dendritic cells. 6,7 Microglia and astrocytes also exhibited elevated BTK activity during inflammatory response. 8,9 Except for BCR signaling, BTK also plays important roles cell-specifically in other immunological pathways, such as FcR signaling and TLR signaling. 10 Furthermore, a series of BTK inhibitors have been tested and/or applied for the treatment of inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), Sjogren's syndrome (SS), multiple sclerosis (MS), systemic lupus erythematosus (SLE), urticaria, pemphigus, idiopathic thrombocytopenic purpura (ITP), IgG4-related disease (RD), etc. 11 Neuroinflammation is considered to be the driver of a broad spectrum of neurological disorders, including autoimmune, neurodegenerative and cerebral ischemic disorders. 12,13 Thus, modulating neuroinflammation was regarded as an effective way to alleviate disease progression. Therefore, more and more studies have emerged to test the possibility of BTK inhibition as a therapeutic approach to regulate neuroinflammatory responses and improve the outcome of diseases. BTK is a 659 amino acid protein and, as a member of the Tec family, is characterized by five domains: pleckstrin homology domain (PH) in N-terminal, TEC homology domain (TH), two Src homology domains 2 (SH2) and 3 (SH3), and the catalytic kinase C-terminal domain. The activation of BTK in BCR signaling involves several steps. Upon recruitment to membrane enabled by the PH domain through PIP 3 , Y551 in the c -Abstract Truncated-

Correction: Tyrosine kinase Btk is required for NK cell activation.

Effects of BTK Signalling in Pathogenic Microorganism Infections

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.

Bruton's Tyrosine Kinase Ablation Inhibits B Cell Responses and Antibody Production for the Prevention of Chronic Rejection in Cardiac Transplantation.

Histone Demethylases UTX and JMJD3 Are Required for NKT Cell Development in Mice

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin

Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System

Tbk1, A Central Kinase In Innate Immune Sensing Of Nucleic Acids And Beyond

Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex–Mediated Inflammatory Arthritis

Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid Cells

Full Activation Of Kinase Protein Kinase B By Phosphoinositide-Dependent Protein Kinase-1 And Mammalian Target Of Rapamycin Complex 2 Is Required For Early Natural Killer Cell Development And Survival

Functional Involvement of TANK‐Binding Kinase 1 in the MyD88‐Dependent NF‐ κ B Pathway Through Syk

TAK1 Negatively Regulates NF-κB and P38 MAP Kinase Activation in Gr-1+CD11b+ Neutrophils.

Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice

Requirement for Membrane Lymphotoxin in Natural Killer Cell Development.

The Kinase Tbk1 Functions in Dendritic Cells to Regulate T Cell Homeostasis, Autoimmunity, and Antitumor Immunity

Cell intrinsic role of NF-κB-inducing kinase in regulating T cell-mediated immune and autoimmune responses

Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment